Clinical trials: SARS
Covid19, SARS-CoV Infection
A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE
This study is randomized, double-blind (blinded for the trial subject and the study physician), placebo-controlled trial in the parallel assignment of the immunogenicity, and safety of the Gam-COVID-Vac combined vector vaccine…
- Trial name
- SPUTNIK-UAE (NCT04656613)
- Testing
- Gam-COVID-Vac
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
SARS-CoV-2
SARS-CoV-2 Safety Study for the Treatment of COVID-19
SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.
- Trial name
- SARS-CoV-2 (NCT06489860)
- Testing
- HIV, Malignant Neoplasms Safety Study for the Treatment of Neoplasms
- Volunteers
- healthy volunteers welcome
- Sponsor
- DHA Coffee Co., Ltd
SARS-CoV-2 Infection
Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine
This study aims to address evidence gaps regarding the safety, reactogenicity and immune responses of a heterologous boost of a single dose of Ad26.COV2.S (half or full dose) at pre-specified time intervals in recipients who are…
- Trial name
- NCT05109559
- Testing
- Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp
- Where
- Thailand
- Volunteers
- 690 people, healthy volunteers welcome
- Sponsor
- Mahidol University
SARS-CoV Infection
Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Since March 2020, the SARS-CoV type coronavirus infection (SARS-CoV-2; nCoV19; COVID-19) is considered pandemic. As early as April 2020, the World Health Organization recommended the implementation of mass screening of…
- Trial name
- SAMILCOV (NCT04550390)
- Testing
- Saliva collection
- Where
- 4 sites in France
- Volunteers
- 329 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
COVID-19 Respiratory Infection
COVID-19 Seroprevalence in Pregnant Women and Blood Donors
The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these…
- Trial name
- CoVERED (NCT04893057)
- Where
- France
- Volunteers
- 797 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Down Syndrome, SARS-CoV-2 Vaccination
Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.
The risk of severe course of SARS-CoV-2 infection in people with Down Syndrome is substantially increased. The risk of death is 3-10 fold higher than in healthy people.
- Trial name
- PRIDE (NCT05145348)
- Testing
- Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)
- Where
- Netherlands
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
SARS-CoV-2
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants aged 18 years and over in China
- Trial name
- NCT05547243
- Testing
- SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Covid19
Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)
SARS-CoV-2 is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, collectively called coronavirus disease-19 (COVID-19).
- Trial name
- TP-SCB-2019001 (NCT05087368)
- Testing
- ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca), CoronaVac (Sinovac Biotech), Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
- Where
- 3 sites in Brazil
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
Covid19 Prevention
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- RESIST (NCT04530396)
- Testing
- Gam-COVID-Vac
- Where
- 23 sites in Russia
- Volunteers
- 33,758 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19
An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens
This is an exploratory phase 3, cohort randomized, observer-blind, multi-center study to evaluate the safety and immunogenicity of a 4th dose of various SARS-CoV-2 vaccines.
- Trial name
- NCT05470803
- Testing
- AstraZeneca/Fiocruz, Pfizer/Wyeth, Clover SCB-2019
- Where
- 3 sites in Brazil
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
Non-hodgkin Lymphoma,B Cell, Vaccination Failure
Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma
The specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and…
- Trial name
- LYMPHO-CoVac (NCT05050461)
- Testing
- Immunological analyses
- Where
- 7 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Versailles Hospital
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
SARS-CoV-2
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.
- Trial name
- NCT05550142
- Testing
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
COVID-19
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
The purpose of the study is to assess safety and immunogenicity of heterologous booster vaccine containing combination of AZD1222 and rAd26-S (one of components of Gam-COVID-Vac vaccine) in adult subjects aged ≥ 18 years old to…
- Trial name
- NCT04686773
- Testing
- AZD1222, rAd26-S
- Where
- Azerbaijan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Covid19, SARS-CoV2 Infection
Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia
There are relevant questions that need to be answered about the effectiveness and safety of COVID-19 vaccines. The objective of this observational study is to follow up the clinical outcomes after vaccination in all the…
- Trial name
- NCT04887246
- Testing
- COVID-19 vaccines
- Where
- Colombia
- Volunteers
- 4,078 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
SARS CoV-2, Developmental Disorder
Neurological Development In Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a virus that causes neurological symptoms in a significant proportion of patients in addition to respiratory symptoms.
- Conditions
- SARS CoV-2, Developmental Disorder, Pregnancy Related
- Trial name
- CRONOS-Kids (NCT06968897)
- Where
- Germany
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Philipps University Marburg
SARS-CoV-2, Seasonal Influenza
A Study of Modified mRNA Vaccines in Healthy Adults
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Trial name
- NCT05397223
- Testing
- mRNA-1273, mRNA-1010, mRNA-1345
- Where
- 8 sites in United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using…
- Trial name
- NCT06919796
- Testing
- COMIRNATY®
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (3~17 years old) Research purpose:Main purpose:To evaluate the safety and tolerability of recombinant New Coronavirus vaccine (CHO cells) in…
- Trial name
- NCT04961359
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Covid19
OCTA Study: Retinal Vascular Changes in Patients With SARS-CoV-2 Infection
This study evaluates the retinal vascular features using optical coherence tomography angiography in patients that have been affected by COVID-19.
- Trial name
- NCT04601012
- Testing
- Optical coherence tomography angiography
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Federico II University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.